JUAN
PASQUAU LIAÑO
Investigador en el periodo 2022-2023
Hospital de Cruces
Barakaldo, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Cruces (9)
2021
-
Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 72, Núm. 9, pp. 1517-1525
2020
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
Annals of Clinical Microbiology and Antimicrobials, Vol. 18, Núm. 1
2018
-
Antibiotic selection in the treatment of acute invasive infections by pseudomonas aeruginosa: Guidelines by the Spanish society of chemotherapy
Revista Espanola de Quimioterapia, Vol. 31, Núm. 1, pp. 78-100
-
High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial
PLoS ONE, Vol. 13, Núm. 4
2015
-
Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: Protocol of a multicentre, randomised, phase III trial
BMJ Open, Vol. 5, Núm. 3
-
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study
HIV Medicine, Vol. 16, Núm. 10, pp. 628-634
2013
-
Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of staphylococcus aureus bacteremia
Clinical Infectious Diseases, Vol. 57, Núm. 9, pp. 1225-1233
2008
-
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313